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Telomeres, which are specialized structures consisting of a large
number of tandem repeats TTAGGG at the end of eukaryotic chro-
mosomes, are lost with each cell division. This progressive short-
ening of telomeres causes chromosomal instability and cell death
(Blackburn, 1992). Telomerase, a ribonucleoprotein complex,
adds telomeric repeats to the 3¢ end of telomeric DNA. This
telomere stabilization by telomerase can lead to unlimited cell
proliferation (Harley et al, 1995). Human telomerase reverse tran-
scriptase (hTERT), which has been purified as human telomerase
catalytic subunits, regulates telomerase activity (Nakayama et al,
1998; Hisatomi et al, 1999). 
Abundant evidence indicates that the regulation of telomerase is
multifactorial in mammalian cells and involves telomerase gene
expression, post-translational protein-protein interactions, and
protein phosphorylation. Several proto-oncogenes and tumour
suppressor genes have been implicated, both directly and indi-
rectly, in the regulation of telomerase activity (Liu, 1999). 
Recent studies showed that normal human mammary epithelial
cells transducted with a mutant p53 gene became immortalized
and reactive for telomerase, and that wild-type p53 gene transduc-
tion inhibited telomerase activity in cancer cells (Chin et al, 1999;
Kondo et al, 1998). The p53 gene, which encodes a cell-cycle
checkpoint protein, has a pivotal role in inducing apoptosis
(Kastan et al, 1995; Fritsche et al, 1993). Those findings suggest a
relationship between p53-dependent apoptosis and telomerase
activity. However, whether and how p53-dependent apoptosis
affect telomerase activity in ovarian cancer is still unknown. 
We conducted the present study to determine the relationship
between p53-dependent apoptosis and telomerase activity in
ovarian cancer cells. 
MATERIALS AND METHODS 
Cell line 
Human ovarian adenocarcinoma cell lines, SK-OV-3 with
homozygous deletion of the p53 gene and KF with wild-type p53
gene were used in this study. SK-OV-3 was obtained from the
American Type Culture Collection. KF was kindly provided by Dr
Kikuchi, National Defense Medical College. SK-OV-3 cells were
maintained in minimum essential medium (Nissui, Tokyo, Japan)
with 10% fetal bovine serum (FBS) in a humidified atmosphere
containing 5% CO2 at 37˚C. KF was maintained in RPMI 1640
medium (Nissui, Tokyo, Japan) with 10% FBS in a humidified
atmosphere containing 5% CO2 at 37˚C.
Cell suppression effect and apoptosis 
Wild-type p53 genes were transfected to SK-OV-3 cells with a
recombinant adenovirus with wild-type p53 gene (AxCAp53).
Infectious units of each virus per cell were 25 MOI for SK-OV-3
according to previous data (Kanamori et al, 1998). A recombinant
adenovirus AxCALacZ, encoding for the bacterial LacZ gene
under the control of the CAG promoter, was used as a control. 
The effect of cisplatin (CDDP) was evaluated by MTT assay 
in SK-OV-3 cells with and without the p53 gene. Briefly, cells 
(104 cells/well) were seeded in 96-well plates and preincubated for
4 h, then incubated for 72 h after exposure to CDDP. Additionally,
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CDDP was added 1 h after infection with the virus, then the cells
were incubated for 72 h. Concentrations of CDDP ranged from 0.9
to 22.2 mM. The dose-response curve was plotted on a semi-log
scale as a percentage of the control cell number obtained from the
untreated sample. The IC50 of SK-OV-3 cells was determined from
the dose-response curve as a percentage of the control cell number
without drugs. The IC50 of KF cells (3.1 mM) was determined by
our previous data (Takahashi et al, 2000). 
For assessment of apoptosis, cells (105 cells/well) were seeded
in 28 cm2 dishes and preincubated for 4 h and CDDP of IC50 was
added. Twenty-four, 48, and 72 h after CDDP exposure, apoptotic
cells were assessed morphologically by staining with Hoechst
33258 (Calbiochem-Novabiochem, San Diego, CA) using 
cells fixed with Clarke fixative (ethanol: acetic acid = 3:1). 
The apoptotic index was defined as follows: apoptotic index 
(%) = 100 ´ apoptotic cells/1000 cells. 
For flow cytometric analysis, cells (2 ´ 106) were collected 24 h
and 48 h after treatment. The samples were trypsinized, fixed in
70% ethanol at 4˚C for 1 h, and then resuspended in PBS
containing 40 mg/ml propidium iodide and 0.1 mg/ml RNase.
After 30 min at 37˚C, the cells were analysed with a FACS Caliber
cytofluorometer (Becton Dickinson, San Jose, CA). 
p53, Bax, Bcl-2, and Bcl-xL protein 
p53, Bax, Bcl-2, and Bcl-xL protein expression were determined by
Western blot analysis. IC50 to CDDP was exposed 48 h after 25 MOI
AxCAp53 infection in SK-OV-3 cells. Twenty-four hours after
CDDP exposure, the cells were solubilized on ice in a lysis buffer 
(50 mM Tris-HCl, 125 mM NaCl, 0.1% NP40, 5 mM ethylenedi-
amine tetraacetic acid, 50 mM NaF, 0.1% phenylmethyl sulfonyl
fluoride, and protease inhibitor) and centrifuged at 25 000 ´ g for 
30 min. The total protein concentration in the supernatant was
measured, and samples of 60 mg protein were separated by elec-
trophoresis on a 4–20% gradient polyacrylamide gel. The separated
proteins were transferred onto a polyvinylnylidene difluoride
membrane (Milipore Co., Bedford, MA). Those proteins were visu-
alized with antimouse or antirabbit IgG coupled to horseradish
peroxidase, using enhanced chemiluminescence according to the
manufacturer’s recommendation. The primary anti-p53 and Bcl-2
monoclonal antibody were DO-7 (DAKO, Glostrup, Denmark) and
Ab-3 (Oncogene Research Product, MA). The anti-Bcl-x and Bax
polyclonal antibody were L-19 and N-20 (Santa Cruz Biotechnology,
Santa Cruz, CA), respectively. As a control, KF cells were used. 
Telomerase assay 
IC50 to CDDP was exposed 48 h after 25 MOI AxCAp53 infection
in SK-OV-3 cells. Twenty-four, 48, and 72 h after CDDP exposure,
samples of SK-OV-3 cells with and without p53 transduction and
KF cells were homogenized in 200 ml of 3-[(3-cholamidopropyl)
dimethylammonio] propanesulfonic acid (CHAPS) lysis buffer,
containing 10 mM Tris-HCl (pH7.5), 1 mM MgCl2, 1 mM EGTA,
0.1 M phenylmethylsulfonyl fluoride, 5 mM 2-mercaptethanol,
0.5% CHAPS, 10% Glycerol, at 4˚C. The suspension was incu-
bated for 30 min on ice and then centrifuged at 15 000 ´ g for 
20 min at 4˚C. The protein concentration of the supernatant was
determined by Bradford assay (Bradford, 1976). 
The telomerase assay was performed using a TRAPEZE Telo-
merase Detection Kit (Oncor, Gaithersburg, MD, USA). Briefly,
cell extracts were assayed in a 50 ml reaction mixture containing 10 ´
TRAP (telomeric repeat amplification protocol) buffer (0.2 mM
Tris-HCl (pH 7.3), 15 mM MgCl2, 630 mM KCl, 0.5% Tween 20, 10
mM EGTA, 0.1% bovine serum albumin), 2.5 mM of each deoxynu-
cleoside triphosphate, 0.1 mg of telomerase substrate primer, 0.1 mg
of Primer Mix, 2 units of Taq DNA polymerase and 0.5 ml of
CHAPS cell extract. After 10 min of incubation at 30˚C, polymerase
chain reaction (PCR) amplification was performed with 30 cycles of
94˚C for 30 s and 60˚C for 30 s. The PCR products were analysed by
electrophoresis on 12% polyacrylamide non-denaturating gels and
stained with SYBR Green I (Molecular Probes, Eugene, ORE,
USA). The gels were photographed using a ATTO Densitograph
Lumino-CCD (Atto Corporation, Tokyo, Japan).
A 150-bp DNA standard was used as an internal telomerase
assay standard (ITAS). SiHa cells, originated from cervical squa-
mous cell carcinoma, were used as a positive control. Telomerase
activity was quantitated on a Macintosh Quadra 840AV computer,
using the public domain National Institutes of Health image
program (written by Wayne Rasband at the US National Institutes
of Health and available from the Internet by anonymous ftp from
zippy.nimh.nih.gov or on floppy disk from NTIS, 5285 Port Royal
Rd, Springfield, VA 22161 USA, part number PB93-504648). The
intensity of telomerase activity was expressed relative to the
above-mentioned internal standard. 
We also examined hTERT with real time PCR according to
Hisatomi et al (1999). Briefly, total RNA was extracted from
cells by the acid guanidinium thiocyanate-phenol-chloroform
extraction method using Isogen (Wako Junyaku, Osaka, Japan)
and DNase I (Takara, Shiga, Japan), and was collected from the
precipitate in ethanol. To prepare standard RNA, PCR product
was cloned into pBluescript vector (Stratagene Co., La Jolla
CA) and was linearised to prevent any activity at the T3
promoter site. Standard RNA was synthesized by using T7 RNA
polymerase and was purified by Isogen and DNase I treatment.
The PCR reaction mixture was prepared using a TaqMan PCR
core reagent kit (PE Applied Biosystems, Norwalk, Conn)
according to the manufacturer’s instructions. The reaction
mixture (50 ml) was prepared containing a final 1 ´ PCR buffer,
200 mM dATP, 200 mM dCTP, 200 mM dGTP, 500 mM dUTP,
0.5 U AmpErase UNG, 2.5 U AmpliTaq Gold, 5 mM MgCl2,
0.25 mM BABO-F: 5¢ -TTTCTACCGGAAGAGTGTCTG-3¢
and 0.1 mM BABO-P probe: 5¢-CAAGTTGCAAAGCATTG-
GAATCAGACA-3¢ (GenBank accession number: AF015950).
A real-time PCR system (ABI PRISM 7700 Sequence Detection
System: PE Applied Biosystems) provided essential information
to quantify the initial target copy number according to Heid et al
(1996). Using 5¢ nuclease activity, a specific fluorescent signal
was generated and measured at each cycle during a run. cDNA
synthesized with random primer(Gibco BRL, Rockville, MD),
and the PCR was made at 50 cycles (94˚C for 30 s, 60˚C for 30
s, 72˚C for 20 s) using primers BABO-F as sense primer and
BABO-R as reverse primer. Probes of BABO-P were designed
to target an internal region between the primers. The probe was
labeled at both ends with fluorescent dyes: fluorescein as a
reporter dye and rhodamine as a quencher dye. After annealing
the probe onto the internal locus of the amplicon, the probe was
cleaved with the 5¢ exonuclease activity of thermostable DNA
polymerase. After cleaving the probe, the reporter dye emission
no longer transferred efficiently to the quencher dye, resulting
in an increase in the reporter dye fluorescent emission spectra.
The fluorogenic samples were excited with a laser (488 nm) and
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PCR amplification using an ABI PRISM 7700 Sequence
Detection system. 
Statistical analysis 
All assays were performed in triplicate. Means for all data were
compared by the Student’s t-test. P < 0.05 was considered statisti-
cally significant. 
RESULTS 
IC50 to CDDP was 12.9 mM for SK-OV-3 cells, 11.8 mM for
AxCALacZ infected SK-OV-3 cells, and 9.2 mM for p53 gene
transducted SK-OV-3 cells. In flow cytometric analysis, p53
gene transduction induced G1 arrest and cells in pre-G1 phase
(apoptosis cells). CDDP increased cells in G2M phase. p53 gene
transduction enhanced the effect of CDDP (Figure 1). Apoptotic
index for cells with p53 gene transduction was significantly
higher, compared with cells without transduction. CDDP signifi-
cantly increased the apoptotic index in both SK-OV-3 cells with
and without p53 gene transduction. The apoptotic index
increased and reach to the peak 48 h after CDDP exposure. p53
gene transduction significantly enhanced CDDP-induced apop-
tosis 24 and 72 h after treatment (Figure 2). 
Figure 3 shows the expression of p53 and p53-associated
proteins in each cell line. p53 protein was expressed after
AxCAp53 infection and enhanced by exposure to CDDP. Bax
protein in SK-OV-3 cells did not differ before and after exposure
to CDDP. In SK-OV-3 cells with transduction of the p53 gene, Bax
protein expression increased after exposure to CDDP. Expression
of Bcl-xL decreased after exposure to CDDP in SK-OV-3 cells
with and without transduction. In KF cells, p53 and Bax protein
expression increased, but expression of Bcl-xL slightly decreased
after exposure to CDDP. The expression of Bcl-2 protein did not
change after exposure to CDDP in either cell line. 
The telomerase activity did not differ among 24, 48, and 72 h after
each treatment. The intensity of telomerase activity was 1.05 ± 0.10
for no exposure control, 1.02 ± 0.13 for CDDP exposure in SK-OV-3
cells, and 0.76 ± 0.10 and 0.78 ± 0.14, respectively, in SK-OV-3 cells
with transduction of p53 gene (Figure 3, 4 A). The hTERT expression
also did not change with time after treatment. The expression of
hTERT mRNA (log copies / mg total RNA) was 4.4 for no exposure
control, 4.7 for CDDP exposure in SK-OV-3 cells, and 3.8 and 3.9,
respectively, in SK-OV-3 cells with transduction of the p53 gene
(Figure 4 B). The telomerase activity in SK-OV-3 cells with the p53
gene was significantly lower compared with the cells without the p53
gene. The telomerase activity for AxCALacZ did not differ from that
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Figure 1 Flow cytometric analysis. p53 gene transduction induced G1
arrest and cells in pre-G1 phase (apoptosis cells). CDDP increased cells in
G2M phase 
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Figure 2 The apoptotic index were assessed morphologically by staining
with Hoechst 33258. CDDP significantly increased the apoptotic index in
both SK-OV-3 cells with and without p53 gene transduction. p53 gene
transduction significantly enhanced CDDP-induced apoptosis 24 and 72 h
after treatment. 
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Figure 3 The expression of p53 and p53-associated proteins in each cell
line. p53 protein expressed after AxCAp53 infection and enhanced by
exposure to CDDP. Bax protein in SK-OV-3 cells did not differ before and
after exposure to CDDP. In SK-OV-3 cells with transduction of p53 gene and
KF cells, Bax protein expression increased after exposure to CDDP.
Expression of Bcl-xL decreased after exposure to CDDP in SK-OV-3 cells
with and without transduction 
p53
SK-OV-3 cells  KF cells
Bax
Bcl-xL
Bcl-2
No
treatment CDDP p53
p53+
CDDP
No
treatment CDDPof non-infected SK-OV-3 cells. CDDP exposure did not affect telom-
erase activity and hTERT expression in either cell line. 
DISCUSSION 
Although several authors have examined the relationship between
p53 and telomerase activity, the results have been contradictory
(Kusumoto et al, 1999; Maxwell et al, 1997; Righetti et al, 1996).
Kusumoto et al demonstrated that the p53 gene transduction
directly inhibited telomerase activity in pancreatic cancer cells
(1999). In contrast, another author showed that telomerase activity
was found to be unaffected by overexpression of p53 in immortal-
ized endothelial cells (1997). Those studies investigated telom-
erase activity in cells that had overexpression of p53. For the
present study, we compared telomerase activity after transduction
of the p53 gene and p53-deficient cells to determine whether p53-
dependent apoptosis affects telomerase activity in ovarian cancer.
In our previous study, the efficiency of the recombinant aden-
ovirus to transduce SK-OV-3 cells was 89% for 6.25 MOI, 94%
for 12.5 MOI and 100% for over 25 MOI (Kanamori et al, 1998).
Based on the data, we chose 25 MOI of AxCAp53 to avoid over-
expression of p53. Additionally, a human ovarian adenocarcinoma
cell lines, KF cells which had wild-type p53 gene were used as a
control. 
In the present study, telomerase activity decreased after transduc-
tion of the p53 gene. This result supports the likelihood that the p53
gene contributed to the shortening of telomeres in a p53-negative
H1299 human non-small cell lung cancer cell line (Mukhopadhyay
et al, 1998). p53 gene transduction not only induced apoptosis but
also caused G1 arrest. Because the p21 gene that arrested the cell
cycle at the G1 phase did not affect telomerase activity (Kusumoto
et al, 1999), p53-dependent apoptosis may directly relate to telo-
merase activity. 
SK-OV-3 cells with p53 gene transduction had higher sensi-
tivity to CDDP than did those without the p53 gene. Additionally,
p53 gene transduction enhanced CDDP-induced apoptosis,
supporting the previous findings that the p53 gene contributes to
sensitivity to CDDP (Kastan et al, 1995; Kanamori et al, 1998;
Sato et al, 1999). Regardless of p53 gene status, the apoptotic
index increased after exposure to CDDP, and apoptosis paralleled
cytotoxity in both cell lines. After exposure to CDDP, Bax protein,
which is directly regulated by p53 gene, increased in KF and p53
gene-transducted SK-OV-3 cells, but not in SK-OV-3 cells without
the p53 gene. The Bcl-2 family competes for Bax homodimeriza-
tion and forms heterodimers. Bcl-xL, which is one of the Bcl-2
family, has an important role in solid tumours, (Marone et al,
1998). Bcl-xL, a functional and structural homologue of Bcl-2,
provides protection from apoptosis (Boise et al, 1993; Henriksen
et al, 1995; Marone et al, 1998). In the present study, the expres-
sion of Bcl-xL decreased after exposure to CDDP in all cell lines.
KF cells have a p53-dependent pathway and SK-OV-3 cells, which
had homozygous deletion of the p53 gene, may have a p53-indepen-
dent pathway. In p53 gene-transducted SK-OV-3 cells, CDDP-indu-
ced apoptosis occurred through p53-dependent and -independent
pathways. The appearance of p53-dependent apoptotic pathway
may cause the higher sensitivity to CDDP in p53-transducted cells.
Although it is reported that stable over-expression of Bcl-2 in cancer
cells is accompanied by increased levels of telomerase activity
(Mandal et al, 1997), Bcl-2 expression did not differ among all cell
lines. 
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Figure 4 Telomerase activity measured by TRAP assay (A) 24 h after
exposure to CDDP. The intensity was quantitated by NIH image (B).
Telomerase activity in SK-OV-3 cells with p53 gene was significantly lower
compared with the cells without the p53 gene. CDDP exposure did not affect
telomerase activity or hTERT expression in either cell line (C) CDDP causes DNA strand breaks especially at guanine residues
followed by apoptosis (Pil et al, 1997). TRAP assay measures
telomerase activity within an artificial system and does not
measure the in vitro activity. It is unlikely that CDDP would have
no effect on telomerase in TRAP assay. Therefore, we also exam-
ined hTERT with real time PCR. A recent study showed that
CDDP reduced telomerase activity in human testicular tumor cells
(Burger et al, 1997). In our series, CDDP did not affect telomerase
activity or hTERT expression in all cell lines. Another study
showed that telomerase activity decreased 24–48 h after exposure
to CDDP, but the phenomenon might relate to cell viability
(Akiyama et al, 1999). In contrast our data demonstrated that both
telomerase activity and hTERT expression did not change with
time after treatment. Consequently, CDDP-induced apoptosis via
p53-dependent and -independent pathway apoptosis did not affect
telomerase activity in ovarian cancer cells. 
Deletion of p53 significantly attenuated the adverse cellular
effects of telomere dysfunction (Chin et al, 1999). In the present
study, the telomere length of SK-OV-3 cells did not differ between
cells with and those without p53 gene transduction (data not
shown), although SK-OV-3 cells showed higher telomerase
activity compared with cells with p53 gene transduction. The dura-
tion may have been too short to change telomere length in our
series. 
In conclusion, the p53 gene may relate to telomerase activity,
but p53-gene-dependent apoptosis does not affect this activity. 
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